Shao Meng Wang

Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA.

Jiangsu Yasheng Pharmaceutical Development Co. Ltd. develops and produces pharmaceutical products. It focuses on research and development of structure-based molecule for cancer drugs. The company was founded by Dajun Yang, Ming Guo, and Shaomeng Wang in 2009 and is headquartered in Hong Kong.

Oncofusion Therapeutics, Inc. operates as oncology development company. It specializes in BET Bromodomain Inhibitors, ERG Inhibitors, EZH2-EED Inhibitors and MMSET/NSD2 Inhibitors. The company was founded in 2012 by Arul M. Chinnaiyan and Shaomeng Wang and is headquartered in Ann Arbor, MI.

Medsyn Biopharma LLC develops therapeutics for cancer. The company was founded by Shaomeng Wang and is headquartered in Malvern, PA.

Oncopia Therapeutics LLC engages in biotechnology research. The company was founded in 2017 and is headquartered in Malvern, PA.

Part of University of Michigan, Rogel Cancer Center provides healthcare services for cancer patients.

Part of Ascentage Pharma Group International Co., Ltd., Ascentage Pharma Group Corp. Ltd. is a Chinese biopharmaceutical company. The private company is based in Hong Kong, Hong Kong. The company was founded by Shao Meng Wang.